Biocon Receives DCGI Nod to Market Abraxane (India)
This article was originally published in PharmAsia News
Executive Summary
Biotech company Biocon Ltd. has received approval from the Drug Controller General of India to market Abraxane, its breast cancer drug. Biocon recently concluded a licensing agreement with U.S.-based Abraxis BioScience Inc. for the commercialization of Abraxane in India. Biocon has completed the required formalities to divest its enzymes business vertical to Novozymes South Asia Pvt Ltd, a wholly-owned subsidiary of Denmark-based Novozymes for Rs453.79 crore. Biocon will use the post tax proceeds of this divestment to strategically focus on its core bio-pharmaceuticals business as well as consider key acquisition opportunities to move up the value chain. (Click here for more - May Require Free Registration
You may also be interested in...
EU Health Ministers To Deliberate Over Commission’s Pharma Strategy
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
EU Approval Of COVID-19 Vaccines Possible In Weeks
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Need a specific report? 1000+ reports available
Buy Reports